20 results on '"Reguart, Noemi"'
Search Results
2. Assessment of a New ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1 Rearrangements in Patients with Non–Small Cell Lung Carcinoma: the ROSING Study
3. Spotlight on Camrelizumab in Advanced Squamous Lung Cancer: Another Feather in the Cap of Chinese Checkpoint Inhibitors
4. Immune-Related Adverse Events and Outcomes in Patients with Advanced Non–Small Cell Lung Cancer: A Predictive Marker of Efficacy?
5. Successful Treatment with Gefitinib in Advanced Non–Small Cell Lung Cancer after Acquired Resistance to Osimertinib
6. Lung Cancer in Spain
7. P1.02-076 DNA Methylation Profiling Unravels a TGF-β Hyperresponse in Tumor Associated Fibroblasts from Lung Cancer Patients
8. OA11.06 Role of Fibroblasts in the Subtype-Specific Therapeutic Effects of Nintedanib in Non-Small Cell Lung Cancer (NSCLC)
9. MA09.05 Nivolumab Alone or with Ipilimumab in Recurrent Small Cell Lung Cancer (SCLC): 2-Year Survival and Updated Analyses from the Checkmate 032 Trial
10. P1.02-050 Acquired Resistance to EGFR Tyrosine Kinase Inhibitors (TKIs) in EGFR-Mutant Lung Adenocarcinoma among Hispanics (Rbiop-CLICaP)
11. MA17.09 Premature Fibroblast Senescence in Large Cell Carcinoma Provides Enhanced Growth and Invasive Advantages to Cancer Cells in Culture and in vivo
12. P3.02b-047 Co-Activation of STAT3 and YAP1 Signaling Pathways Limits EGFR Inhibitor Response in Lung Cancer
13. Assessment of ALK Status by FISH on 1000 Spanish Non-Small Cell Lung Cancer Patients
14. P1.03: Utility of a Combined Panel of Six Serum Tumor Markers for Lung Cancer
15. O.01: Acquired Resistance to EGFR-TKIs in EGFR-Mutant Lung Adenocarcinoma Among Hispanics (RBIOP-CLICaP)
16. Assessment of a New ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1Rearrangements in Patients with Non–Small Cell Lung Carcinoma: the ROSING Study
17. PS01.60: Ph Ib/II, Trial of INC280 ± Erlotinib vs Platinum + Pemetrexed in Adult pts with EGFR-Mutated, cMET amplified, EGFR TKI Resistant, Advanced NSCLC: Topic: Medical Oncology
18. P2-092: 14-3-3 sigma and checkpoint with forkhead and ring finger (CHFR) methylation in serum in erlotinib-treated non-small-cell lung cancer (NSCLC) patients (p) with EGFR mutations
19. Wood-Smoke Exposure (WSE) as a Predictor of Response and Survival in Erlotinib-Treated Non-small Cell Lung Cancer (NSCLC) Patients
20. 14-3-3 sigma and checkpoint with forkhead and ring finger (CHFR) methylation in serum in erlotinib-treated non-small-cell lung cancer (NSCLC) patients (p) with EGFR mutations.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.